Clinical trial · Interventional
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination With Paclitaxel and Carboplatin for Patients With Advanced or Metastatic Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin. Paclitaxel and carboplatin will be administered on a standard regimen every 3 weeks at standard doses. BMS-690514 will be given in the interval at escalating doses until the maximum tolerated dose (MTD) is identified. An additional cohort of subjects will be treated with BMS-690514 at the MTD in combination with Paclitaxel and carboplatin
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer (Solid Tumors) | Malignant Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-690514 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: BMS-690514
Primary outcomes (1)
- measure
- To assess safety and tolerability and to identify a dose for BMS-690514 in combination with paclitaxel/carboplatin for Phase II evaluation
- timeFrame
- upon occurrence
Secondary outcomes (2)
- measure
- Describe anti-tumor activity
- timeFrame
- upon occurence
- measure
- Obtain blood, plasma and fresh and/or archived tumor tissue for exploratory research
- timeFrame
- upon occurence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced or metastatic solid tumors for whom paclitaxel/carboplatin is considered an appropriate therapy * Centrally located squamous cell carcinoma of the lung is permitted * ECOG performance status of 0-1 * Life expectancy of at least 3 months * Men and women age 18 and above Exclusion Criteria: * Symptomatic brain metastases. Patients with signs for symptoms of brain metastases are ineligible unless brain metastases are ruled out by CT or MRI * Peripheral neuropathy ≥Grade 1 for any reason * History of thromboembolic disease or bleeding diatheses within the last 6 months * Women of child bearing potential without adequate contraception, breastfeeding, or pregnant * Serious, uncontrolled medical disorder or active infection * Uncontrolled or significant cardiac disease * Uncontrolled hypertension (150/100) * Allergy to Cremophor EL®
References
Publications (0)
Data not yet available